Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:00 am ET and host investor meetings throughout the day.

GlobeNewsWire • Nov 26, 2025

Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth

Krystal Biotech is rated a buy after a strong Vyjuvek launch, but the current valuation reflects premium margins and aggressive global expansion projections. Vyjuvek's US sales growth has plateaued, but international rollouts in Europe and Japan are expected to drive further sales growth, with management targeting $1B in peak sales. KRYS pipeline catalysts include KB803 (ophthalmology), KB407 (cystic fibrosis), and KB801 (neurotrophic keratitis), with key data readouts over the next year.

Seeking Alpha • Nov 16, 2025

Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript

Krystal Biotech, Inc. ( KRYS ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Stephane Paquette - Vice President of Corporate Development Krish Krishnan - Founder, Chairman, President & CEO Laurent Goux - Senior VP & GM of Europe Suma Krishnan - Founder, President of R&D and Director Kathryn Romano - Executive VP & Chief Accounting Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Ritu Baral - TD Cowen, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Samantha Corwin - William Blair & Company L.L.C., Research Division Alexa Deemer - Cantor Fitzgerald & Co., Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Presentation Operator Thank you for standing by, and welcome to the Krystal Biotech Third Quarter 2025 Earnings Call.

Seeking Alpha • Nov 3, 2025

Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade)

Krystal Biotech (KRYS) reported strong Q3 results, with Vyjuvek delivering $97.8M revenue, 96% gross margin, and a new at-home use label. KRYS's disciplined operating expenses and robust cash position support profitability, while pipeline progress in cystic fibrosis and DEB eye therapy adds optionality. The FDA's Platform Technology Designation for KRYS's HSV-1 vector accelerates development, enhancing competitive positioning in gene therapy markets.

Seeking Alpha • Nov 3, 2025

Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 27, 2025

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.

Zacks Investment Research • Sep 30, 2025

Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update

KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.

Zacks Investment Research • Sep 16, 2025

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

The U.S. Food and Drug Administration (FDA) on Monday approved Krystal Biotech, Inc.'s KRYS label update for Vyjuvek (beremagene geperpavec-svdt).

Benzinga • Sep 15, 2025

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) approved a label update for VYJUVEK® (beremagene geperpavec-svdt) that expands the VYJUVEK eligible patient population to include dystrophic epidermolysis bullosa (DEB) patients from birth and provides patients full flexibility with respect to VYJUVEK application and managing wound dressings.

GlobeNewsWire • Sep 15, 2025

Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2025